Skip to main content

Advertisement

Table 3 Incidence of hematological and nonhematological toxicities

From: Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer

Type of toxicity Grade 1 to 2 Grade 3 to 4
  Ce-SOX SOX P Ce-SOX SOX P
Hematological 22 (73.3) 17 (65.4) 0.52 10 (33.3) 11 (42.3) 0.58
Thrombocytopenia 6 (20.0) 5 (19.2) 0.94 2 (6.6) 2 (7.7) 1.0
Neutropenia 16 (53.3) 12 (46.2) 0.59 8 (26.7) 9 (34.6) 0.57
Nonhematological 16 (53.3) 21 (80.8) 0.03 3 (10.0) 5 (19.2) 0.53
Nausea and vomiting 1 (3.3) 8 (30.8) 0.008 1 (3.3) 2 (7.7) 0.59
Diarrhea 0 (0) 1 (3.8) 0.46 0 (0) 1 (3.8) 0.46
Mucositis 1 (3.3) 2 (7.7) 0.59 0 (0) 0 (0) -
Hand-foot syndrome 2 (6.7) 1 (3.8) 0.55 1 (3.3) 1 (3.8) 1.0
Peripheral neuropathy 8 (26.7) 1 (3.8) 0.029 1 (3.3) 0 (0) 0.68
Hepatic dysfunction 3 (10.0) 2 (7.7) 0.67 0 (0) 1 (3.8) 0.72
Renal dysfunction 1 (3.3) 6 (23.1) 0.04 0 (0) 0 (0) -